Oak Ridge Investments LLC Trims Stock Holdings in argenx SE (NASDAQ:ARGX)

Oak Ridge Investments LLC decreased its stake in shares of argenx SE (NASDAQ:ARGX) by 60.4% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,769 shares of the company’s stock after selling 2,696 shares during the period. Oak Ridge Investments LLC’s holdings in argenx were worth $1,088,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Envestnet Asset Management Inc. boosted its position in shares of argenx by 13.8% in the second quarter. Envestnet Asset Management Inc. now owns 62,999 shares of the company’s stock valued at $27,092,000 after acquiring an additional 7,645 shares during the period. Dimensional Fund Advisors LP lifted its stake in argenx by 8.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 19,388 shares of the company’s stock worth $8,339,000 after purchasing an additional 1,438 shares in the last quarter. Wealth Alliance boosted its stake in argenx by 4.8% during the second quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after buying an additional 29 shares during the period. XTX Topco Ltd bought a new stake in shares of argenx during the 2nd quarter valued at about $1,435,000. Finally, Sei Investments Co. grew its holdings in shares of argenx by 15.2% during the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock worth $164,079,000 after purchasing an additional 50,477 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of NASDAQ:ARGX opened at $640.52 on Friday. The stock’s 50-day moving average is $620.19 and its 200 day moving average is $556.51. The company has a market cap of $38.67 billion, a PE ratio of -727.86 and a beta of 0.59. argenx SE has a 1 year low of $349.86 and a 1 year high of $678.21.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The company had revenue of $588.88 million during the quarter, compared to the consensus estimate of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter in the prior year, the company earned ($1.25) earnings per share. Analysts expect that argenx SE will post 2.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research report on Friday, November 1st. Oppenheimer reaffirmed an “outperform” rating and set a $675.00 price objective (up from $646.00) on shares of argenx in a report on Thursday, November 21st. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Citigroup lifted their price target on argenx from $512.00 to $635.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Finally, Guggenheim increased their price objective on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $658.39.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.